The Experts below are selected from a list of 6765 Experts worldwide ranked by ideXlab platform
José Manuel González-buitrago - One of the best experts on this subject based on the ideXlab platform.
-
Anti-nucleosome, anti-chromatin, anti-dsDNA and anti-Histone Antibody reactivity in systemic lupus erythematosus.
Clinical Chemistry and Laboratory Medicine (CCLM), 2004Co-Authors: Concepción González, Belén García-berrocal, Oscar Herraez, José Alejandro Navajo, José Manuel González-buitragoAbstract:Anti-nucleosome (anti-chromatin) antibodies play a key role in the pathogenesis of systemic lupus erythematosus (SLE). The objective of the present study was to determine the clinical significance of anti-nucleosome (anti-chromatin) antibodies, anti-dsDNA antibodies and anti-Histone antibodies in patients with SLE in relation to patients with positive nuclear antibodies and healthy controls. We measured anti-nucleosome (anti-chromatin) antibodies, anti-dsDNA antibodies and anti-Histone antibodies in 70 patients with SLE, 35 antinuclear Antibody (ANA)-positive subjects without autoimmune disease and 35 blood donors. All antibodies were determined by enzyme-linked immunosorbent assay (ELISA). We obtained the receiver operating characteristic (ROC) curve and the area under the curve (AUC) for each autoAntibody. Likewise, we obtained the sensitivity, specificity and positive and negative likelihood ratios for each autoAntibody. The highest AUC was obtained for anti-nucleosome (0.898) and the lowest AUC for a kit for anti-dsDNA (0.725). Stratification of the control group (ANA-positive subjects without autoimmune disease and blood donors) produced significant changes in the AUCs; all AUCs decreased when ANA-positive patients without autoimmune disease were considered as controls and all AUCs increased when blood donors were considered as controls. These effects were less marked in anti-dsDNA antibodies. We observed discrepancies between kits (anti-nucleosome and anti-chromatin and two for anti-dsDNA). The highest sensitivity for SLE was obtained for anti-nucleosome antibodies (86%) and the highest specificity was obtained for anti-dsDNA antibodies (90%). In conclusion, anti-nucleosome and anti-chromatin kits show different degrees of clinical accuracy due to the cut-off selected by the manufacturer. Once the kits with the best performance and the optimal cut-offs have been selected, anti-nucleosome antibodies and anti-dsDNA antibodies provide similar information in established SLE.
Concepción González - One of the best experts on this subject based on the ideXlab platform.
-
Anti-nucleosome, anti-chromatin, anti-dsDNA and anti-Histone Antibody reactivity in systemic lupus erythematosus.
Clinical Chemistry and Laboratory Medicine (CCLM), 2004Co-Authors: Concepción González, Belén García-berrocal, Oscar Herraez, José Alejandro Navajo, José Manuel González-buitragoAbstract:Anti-nucleosome (anti-chromatin) antibodies play a key role in the pathogenesis of systemic lupus erythematosus (SLE). The objective of the present study was to determine the clinical significance of anti-nucleosome (anti-chromatin) antibodies, anti-dsDNA antibodies and anti-Histone antibodies in patients with SLE in relation to patients with positive nuclear antibodies and healthy controls. We measured anti-nucleosome (anti-chromatin) antibodies, anti-dsDNA antibodies and anti-Histone antibodies in 70 patients with SLE, 35 antinuclear Antibody (ANA)-positive subjects without autoimmune disease and 35 blood donors. All antibodies were determined by enzyme-linked immunosorbent assay (ELISA). We obtained the receiver operating characteristic (ROC) curve and the area under the curve (AUC) for each autoAntibody. Likewise, we obtained the sensitivity, specificity and positive and negative likelihood ratios for each autoAntibody. The highest AUC was obtained for anti-nucleosome (0.898) and the lowest AUC for a kit for anti-dsDNA (0.725). Stratification of the control group (ANA-positive subjects without autoimmune disease and blood donors) produced significant changes in the AUCs; all AUCs decreased when ANA-positive patients without autoimmune disease were considered as controls and all AUCs increased when blood donors were considered as controls. These effects were less marked in anti-dsDNA antibodies. We observed discrepancies between kits (anti-nucleosome and anti-chromatin and two for anti-dsDNA). The highest sensitivity for SLE was obtained for anti-nucleosome antibodies (86%) and the highest specificity was obtained for anti-dsDNA antibodies (90%). In conclusion, anti-nucleosome and anti-chromatin kits show different degrees of clinical accuracy due to the cut-off selected by the manufacturer. Once the kits with the best performance and the optimal cut-offs have been selected, anti-nucleosome antibodies and anti-dsDNA antibodies provide similar information in established SLE.
D. Rigal - One of the best experts on this subject based on the ideXlab platform.
-
Autoantibodies to Histone, DNA and nucleosome antigens in canine systemic lupus erythematosus.
Clinical & Experimental Immunology, 2008Co-Authors: Marc Monestier, J.c. Monier, K. E. Novick, E. T. Karam, Luc Chabanne, D. RigalAbstract:Dogs can develop systemic lupus erythematosus syndromes that are clinically similar to those seen in humans. In contrast, previous observations suggest differences in their autoAntibody reactivity patterns against Histones and DNA which are components of the nucleosome in chromatin. The objective of this study was to assess comprehensively the levels of autoantibodies against Histone, DNA and nucleosome antigens in a population of lupus dogs. The specificities of antibodies in lupus and control dog sera were determined using IgM- and IgG-specific reagents in an ELISA against a variety of chromatin antigens. When compared with control sera, IgG antibodies to individual Histones H1, H2A, H3 and H4 were significantly higher in the lupus group. In contrast, we did not detect IgG antibodies specific for H2B, H2A-H2B, DNA, H2A-H2B-DNA or nucleosome in lupus dogs. There was no significant increase in any of the IgM specificities tested. Therefore, the reactivity pattern to nucleosome antigens in canine lupus is restricted to IgG antibodies against individual Histones H1, H2A, H3 and H4. This stands in contrast with human and murine lupus, where autoantibodies are directed against a wide variety of nucleosomal determinants, suggesting that unique mechanisms lead to the expansion of anti-Histone Antibody clones in canine lupus. The high incidence of glomerulonephritis in dog lupus suggests that anti-DNA antibodies are not required for the development of this complication, whereas IgG anti-Histone antibodies may be relevant to its pathogenesis.
Belén García-berrocal - One of the best experts on this subject based on the ideXlab platform.
-
Anti-nucleosome, anti-chromatin, anti-dsDNA and anti-Histone Antibody reactivity in systemic lupus erythematosus.
Clinical Chemistry and Laboratory Medicine (CCLM), 2004Co-Authors: Concepción González, Belén García-berrocal, Oscar Herraez, José Alejandro Navajo, José Manuel González-buitragoAbstract:Anti-nucleosome (anti-chromatin) antibodies play a key role in the pathogenesis of systemic lupus erythematosus (SLE). The objective of the present study was to determine the clinical significance of anti-nucleosome (anti-chromatin) antibodies, anti-dsDNA antibodies and anti-Histone antibodies in patients with SLE in relation to patients with positive nuclear antibodies and healthy controls. We measured anti-nucleosome (anti-chromatin) antibodies, anti-dsDNA antibodies and anti-Histone antibodies in 70 patients with SLE, 35 antinuclear Antibody (ANA)-positive subjects without autoimmune disease and 35 blood donors. All antibodies were determined by enzyme-linked immunosorbent assay (ELISA). We obtained the receiver operating characteristic (ROC) curve and the area under the curve (AUC) for each autoAntibody. Likewise, we obtained the sensitivity, specificity and positive and negative likelihood ratios for each autoAntibody. The highest AUC was obtained for anti-nucleosome (0.898) and the lowest AUC for a kit for anti-dsDNA (0.725). Stratification of the control group (ANA-positive subjects without autoimmune disease and blood donors) produced significant changes in the AUCs; all AUCs decreased when ANA-positive patients without autoimmune disease were considered as controls and all AUCs increased when blood donors were considered as controls. These effects were less marked in anti-dsDNA antibodies. We observed discrepancies between kits (anti-nucleosome and anti-chromatin and two for anti-dsDNA). The highest sensitivity for SLE was obtained for anti-nucleosome antibodies (86%) and the highest specificity was obtained for anti-dsDNA antibodies (90%). In conclusion, anti-nucleosome and anti-chromatin kits show different degrees of clinical accuracy due to the cut-off selected by the manufacturer. Once the kits with the best performance and the optimal cut-offs have been selected, anti-nucleosome antibodies and anti-dsDNA antibodies provide similar information in established SLE.
José Alejandro Navajo - One of the best experts on this subject based on the ideXlab platform.
-
Anti-nucleosome, anti-chromatin, anti-dsDNA and anti-Histone Antibody reactivity in systemic lupus erythematosus.
Clinical Chemistry and Laboratory Medicine (CCLM), 2004Co-Authors: Concepción González, Belén García-berrocal, Oscar Herraez, José Alejandro Navajo, José Manuel González-buitragoAbstract:Anti-nucleosome (anti-chromatin) antibodies play a key role in the pathogenesis of systemic lupus erythematosus (SLE). The objective of the present study was to determine the clinical significance of anti-nucleosome (anti-chromatin) antibodies, anti-dsDNA antibodies and anti-Histone antibodies in patients with SLE in relation to patients with positive nuclear antibodies and healthy controls. We measured anti-nucleosome (anti-chromatin) antibodies, anti-dsDNA antibodies and anti-Histone antibodies in 70 patients with SLE, 35 antinuclear Antibody (ANA)-positive subjects without autoimmune disease and 35 blood donors. All antibodies were determined by enzyme-linked immunosorbent assay (ELISA). We obtained the receiver operating characteristic (ROC) curve and the area under the curve (AUC) for each autoAntibody. Likewise, we obtained the sensitivity, specificity and positive and negative likelihood ratios for each autoAntibody. The highest AUC was obtained for anti-nucleosome (0.898) and the lowest AUC for a kit for anti-dsDNA (0.725). Stratification of the control group (ANA-positive subjects without autoimmune disease and blood donors) produced significant changes in the AUCs; all AUCs decreased when ANA-positive patients without autoimmune disease were considered as controls and all AUCs increased when blood donors were considered as controls. These effects were less marked in anti-dsDNA antibodies. We observed discrepancies between kits (anti-nucleosome and anti-chromatin and two for anti-dsDNA). The highest sensitivity for SLE was obtained for anti-nucleosome antibodies (86%) and the highest specificity was obtained for anti-dsDNA antibodies (90%). In conclusion, anti-nucleosome and anti-chromatin kits show different degrees of clinical accuracy due to the cut-off selected by the manufacturer. Once the kits with the best performance and the optimal cut-offs have been selected, anti-nucleosome antibodies and anti-dsDNA antibodies provide similar information in established SLE.